Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks setting
about
Immunotherapy for Bone and Soft Tissue SarcomasAdjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience.Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agentsIndividualised risk assessment for local recurrence and distant metastases in a retrospective transatlantic cohort of 687 patients with high-grade soft tissue sarcomas of the extremities: a multistate model.Patterns of disease relapse in primary extremity soft-tissue sarcoma.The diagnostic and prognostic value of interleukin-6 in patients with soft tissue sarcomas.We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas.High-grade soft tissue sarcomas of the extremities: surgical margins influence only local recurrence not overall survival.Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.Feasibility and clinical value of CT-guided (125)I brachytherapy for metastatic soft tissue sarcoma after first-line chemotherapy failure.Diagnosis and treatment of soft-tissue sarcomas of the extremities and trunk.Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases.
P2860
Q28088363-A3C96DF4-3D23-42D7-B427-E83320B5CD34Q36573310-898C0FC6-83B2-4E29-AA38-1631ED80B85EQ37106770-171007ED-09F6-4038-8A0D-F561DA37CDDEQ37654201-84BE83D7-68A8-4186-9E2D-E9A5E822F09AQ40629989-B0FD1CCA-CC53-4B24-AA41-187D06A0EBCDQ41550528-C7F33159-4E50-4AF8-A968-D7FA6503ADF4Q42333740-A2B204CF-BF7E-4493-A9ED-07905A713D26Q43772198-BFDA2BD7-8154-4F4B-AF26-CFFEF5DF89C9Q47199914-1F5E65E0-FAA3-44D3-864B-84CC10984883Q49691413-77B56B75-8920-4875-895E-453BAA711DC5Q52418969-CD29F949-D606-4DAD-9E01-D6060E07CBE0Q55216228-F16529B5-4CF3-453B-A2E4-B5429185751F
P2860
Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks setting
description
im Juli 2014 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 10 July 2014
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2014
@uk
name
Prognostic factors and impact ...... in the competing risks setting
@en
Prognostic factors and impact ...... in the competing risks setting
@nl
type
label
Prognostic factors and impact ...... in the competing risks setting
@en
Prognostic factors and impact ...... in the competing risks setting
@nl
prefLabel
Prognostic factors and impact ...... in the competing risks setting
@en
Prognostic factors and impact ...... in the competing risks setting
@nl
P2093
P2860
P50
P356
P1433
P1476
Prognostic factors and impact ...... in the competing risks setting
@en
P2093
Antoine Italiano
Axel Le Cesne
Christine Chevreau
Corinne Delcambre
Dominique Ranchere-Vince
Jean Mendiboure
Jean-Jacques Michels
Marick Lae
Philippe Terrier
Sophie Le Guellec
P2860
P304
P356
10.1002/CNCR.28885
P407
P577
2014-07-10T00:00:00Z